AUS
NZ
UK
CA
USA
IND
Highlights
- Clinical trials in UK have witnessed a 41% decline from the period of 2017 to 2021, as per ABPI’s report.
- The fall in trials poses a severe threat to the country’s status as a clinical research hub.
- The report also shows that the NHS has lost around £447 million from 2020 to 2021 due to the lack of research.
According to a latest industry report, UK has witnessed a 41% decline in the number of clinical trials from 2017 to 2021. The Association of the British Pharmaceutical Industry (ABPI) study highlights that this fall in trials poses a severe threat to the country’s status as a clinical research hub..
The UK government has claimed that it has reinforced its status as an international science superpower. In fact, clinical studies were carried out during Covid-19, which led to the discoveries of vaccines and medications. But the dip in clinical trials of late has darkened the UK’s outlook, pushing its rankings from 4th to 10th..
©2022 Kalkine Media®
This was mainly driven by new late-stage trials, which are key to obtaining regulatory authorisations for medicines that have been halved. ABPI’s director of research policy, Jennifer Harris, has reportedly said that it is becoming tougher to carry out clinical trials in the UK, and thus the industry is looking for alternatives.
Reduced research lowers the advantages to patients and burdens the already struggling National Health System (NHS). According to a recent report, the NHS has lost around £447 million from 2020 to 2021 due to the lack of research.
Amid these developments, UK investors can keep an eye on the pharmaceutical stocks trading on the London Stock Exchange.
AstraZeneca plc (LON: AZN)
The YTD (year to date) return of the research-based biopharmaceutical firm, AstraZeneca plc, stands at 12.11% as of 20 October. Meanwhile, the one-year return of the firm stands at 11.31%. AZN shares witnessed a dip of 0.77% on Thursday morning at around 8:05 AM (GMT+1), trading at GBX 9,734.00. With a market capitalisation of £1,53,400.20, the FTSE100 firm’s EPS (earning per share) stands at 0.08, along with a turnover (on the book) of £5,718,162.85.
Indivior plc (LON: INDV)
The YTD return of the speciality pharmaceuticals company, Indivior plc stands at 10.74% as of 20 October. Meanwhile, the one-year return of the firm stands at 23.31%. INDV shares were experiencing a fall of 0.42% on Thursday morning at around 8:20 AM (GMT+1), trading at GBX 1,427.00. With a market capitalisation of £1,988.07, the FTSE250 firm’s EPS stands at 1.40, along with a turnover (on the book) of £43,456.05.
GSK plc (LON: GSK)
The YTD return of the pharmaceutical and biotechnology group, GSK plc, stands at -15.03% as of 20 October. Meanwhile, the one-year return of the firm stands at -2.97%. GSK shares were experiencing a drop of 1.23% on Thursday morning at around 8:25 AM (GMT+1), trading at GBX 1,365.20. With a market capitalisation of £56,740.41, the FTSE100 firm’s EPS stands at 1.10, along with a turnover (on the book) of £3,919,535.42.
